Ongoing collaboration

In April 2020, an agreement was signed between Revotek and the University of Tennessee Health Sciences Center (UTHSC), in which Revotek provided 3-d and Biosynsphere bioprinting technologies and facilities to UTHSC. This is the first advertising agreement for Biosynsphere technology. , both parties have strategic partners in clinical studies and clinical programs of mobile regenerative medicine with stem, and have since cooperated in many areas, such as the FDA’s application of bioprinted blood vessels in 3-d mobile stem for clinical trials.